Product
Recombinant Interferon Alfa-2b
Aliases
Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, interferon alfa-2b (9 other aliases)
Name
Interferon alfa-2b
9 clinical trials
1 drug
33 indications
Indication
Prostate CancerIndication
Prostate Cancer, Stage III AJCC v8Indication
Prostate Cancer Stage IIIB AJCC v8Indication
Melanoma of Unknown PrimaryIndication
MelanomaIndication
Cutaneous MelanomaIndication
Stage IV Cutaneous MelanomaIndication
Breast CancerIndication
Stage II Breast CancerIndication
Stage IIB Breast CancerIndication
Breast CarcinomaIndication
Estrogen Receptor NegativeIndication
HER2/Neu NegativeIndication
Progesterone Receptor NegativeIndication
Stage 0 Breast CancerIndication
Breast Cancer AJCC Stage IAIndication
Stage IIA Breast CancerIndication
Triple-Negative Breast CarcinomaIndication
HLA-A2 Positive Cells PresentIndication
Colorectal Neuroendocrine Tumor G1Indication
Gastric Neuroendocrine Tumor G1Indication
Neuroendocrine TumorIndication
Triple-Negative Breast CancerIndication
Breast Cancer, Anatomic Stage IVIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
COVID-19Indication
Stage IIIA Cutaneous Melanoma AJCC v7Indication
Metastatic Mucosal MelanomaIndication
Metastatic Non-Cutaneous MelanomaIndication
Recurrent Non-Cutaneous MelanomaDrug
interferon alfaClinical trial
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating RegimenStatus: , Estimated PCD: 2024-05-29
Clinical trial
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk MelanomaStatus: Active (not recruiting), Estimated PCD: 2019-02-15
Clinical trial
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 ResistanceStatus: Recruiting, Estimated PCD: 2025-08-22
Clinical trial
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid PatientsStatus: Active (not recruiting), Estimated PCD: 2015-01-01
Clinical trial
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2020-09-02
Clinical trial
Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19Status: , Estimated PCD: 2023-11-17
Clinical trial
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2017-08-08
Clinical trial
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-09-15